Uncle Sam's Orders: Emergent Scores $107 Mil. For Anthrax Plant, While Bavarian Nordic Delivers On Smallpox
This article was originally published in The Pink Sheet Daily
Executive Summary
Government funding for the BioThrax plant suggests there are doubts other new treatments will be ready soon. But funding for the BioShield program may be reduced during congressional debate on appropriations.
You may also be interested in...
Smallpox Discovery Prompts FDA Action Plan; Move To White Oak Unchanged
FDA scientist’s discovery of decades-old vials of smallpox at lab on NIH campus are a reminder of the unsettled debate on whether governments should keep smallpox stock to aid development of antivirals.
Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.
Labeling Changes For Products In Strategic National Stockpile To Be Controlled By FDA, Not Firms
Final rule allows CDC officials to request waivers or alternatives to labeling of certain medical products in a national emergency. Industry had wanted to narrow the waiver powers; hospitals had wanted to broaden them. FDA declined to do either.